← Stack Research Tool

Pair page

5-Amino-1MQ with AICAR

Mechanism-tag overlap and published literature for 5-Amino-1MQ and AICAR, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.

Mechanism overlap

Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.

5-AMINO-1MQ AICAR 1 UNIQUE TAGS 1 UNIQUE TAGS 0 SHARED
5-Amino-1MQ unique nnmt-inhibitor
Shared none
AICAR unique ampk-activator-exercise-mimetic

Co-administration notes from the literature

Verbatim summary text pulled from each compound's profile data. Researchers studying 5-Amino-1MQ and AICAR have published these mechanism-level observations. Not a co-administration recommendation.

Evidence level: mechanistic only

5-Amino-1MQ preserves NAD+ pools (NNMT inhibition); AICAR activates AMPK. Both support mitochondrial function through complementary mechanisms. Combination use is community speculation rather than established practice.

Quick facts

5-Amino-1MQ

RouteOral / SubQ (preclinical)
Half-lifeNot listed
FDA statusNot approved
WADANot specifically named
Full 5-Amino-1MQ profile →

AICAR

RouteIV (clinical studies) / SubQ / Oral
Half-life~1.5 h IV (parent); intracellular ZMP longer
FDA statusNot approved
WADABanned S4 (Hormone & Metabolic Modulators)
Full AICAR profile →

Literature table

Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.

Year Compound Source Finding
20245-Amino-1MQBabula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes Obes Metab. 2024. PMID: 39161060. (Pharmacokinetic characterization of 5A1MQ after IV, oral, and SubQ dosing in DIO m… PMID 39161060preclinical, in vivo
20185-Amino-1MQNeelakantan H, Vance V, Wetzel MD, Wang HL, McHardy SF, Finnerty CC, Hommel JD, Watowich SJ. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141-152. PMID: 2… PMID 29155147preclinical, in vivo
20175-Amino-1MQNeelakantan H, Wang HY, Vance V, Hommel JD, McHardy SF, Watowich SJ. Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase. J Med Chem. 2017;60(12):5015-5028. PMID: 28493686. PMID 28493686mechanism / discovery
20175-Amino-1MQPissios P. Nicotinamide N-Methyltransferase: More Than a Vitamin B3 Clearance Enzyme. Trends Endocrinol Metab. 2017;28(5):340-353. PMID: 28291578. PMID 28291578pharmacology
20225-Amino-1MQBrightwell CR, Latham CM, Thomas NT, Keeble AR, Murach KA, Fry CS. A glitch in the matrix: the pivotal role for extracellular matrix remodeling during muscle hypertrophy. Am J Physiol Cell Physiol. 2022;323(3):C763-C771. PMID: 35876283. (Satellite-cell / NNMT context.) PMID 35876283research article
20215-Amino-1MQCampagna R, Pozzi V, Sartini D, Salvolini E, Brisigotti V, Molinelli E, Campanati A, Offidani A, Emanuelli M. Beyond Nicotinamide Metabolism: Potential Role of Nicotinamide N-Methyltransferase as a Biomarker in Skin Cancers. Cancers (Basel). 2021;13(19):4943. PMID: 34638428. PMID 34638428research article
20215-Amino-1MQRoberti A, Fernández AF, Fraga MF. Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation. Mol Metab. 2021;45:101165. PMID: 33453418. PMID 33453418research article
20195-Amino-1MQNeelakantan H, Brightwell CR, Graber TG, Maroto R, Wang HL, McHardy SF, Papaconstantinou J, Fry CS, Watowich SJ. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochem Ph… PMID 30885768research article
20185-Amino-1MQKomatsu M, Kanda T, Urai H, Kurokochi A, Kitahama R, Shigaki S, Ono T, Yukioka H, Hasegawa K, Tokuyama H, Kawabe H, Wakino S, Itoh H. NNMT activation can contribute to the development of fatty liver disease by modulating the NAD+ metabolism. Sci Rep. 2018;8(1):8637. PMID: 298721… PMID 29872148research article
20155-Amino-1MQHong S, Moreno-Navarrete JM, Wei X, Kikukawa Y, Tzameli I, Prasad D, Lee Y, Asara JM, Fernandez-Real JM, Maratos-Flier E, Pissios P. Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nat Med. 2015;21(8):887-894. PMID: 261… PMID 26168293research article
20145-Amino-1MQKraus D, Yang Q, Kong D, Banks AS, Zhang L, Rodgers JT, Pirinen E, Pulinilkunnil TC, Gong F, Wang YC, Cen Y, Sauve AA, Asara JM, Peroni OD, Monia BP, Bhanot S, Alhonen L, Puigserver P, Kahn BB. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nat… PMID 24717514research article
20135-Amino-1MQUlanovskaya OA, Zuhl AM, Cravatt BF. NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nat Chem Biol. 2013;9(5):300-306. PMID: 23455543. PMID 23455543research article
1997AICARMangano DT; Multicenter Study of Perioperative Ischemia Research Group. Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. JAMA. 1997;277(4):325-332. PMID: 9002496. (Meta-analysis of acade… PMID 9002496meta-analysis
2013AICARVan Den Neste E, Cazin B, Janssens A, González-Barca E, Terol MJ, Levy V, Pérez de Oteyza J, Zachee P, Saunders A, de Frias M, Campàs C. Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicentre phase I/II study. Cancer Chemother Pharmacol… PMID 23228967human trial, Phase 1
2008AICARNarkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, Kang H, Shaw RJ, Evans RM. AMPK and PPARδ agonists are exercise mimetics. Cell. 2008;134(3):405-415. PMID: 18674809. (The definitive "exercise in a pill" mouse endurance paper.) PMID 18674809preclinical, in vivo
1997AICARMerrill GF, Kurth EJ, Hardie DG, Winder WW. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol. 1997;273(6 Pt 1):E1107-E1112. PMID: 9435525. (Foundational AMPK-activation mechanistic paper.) PMID 9435525preclinical, in vivo
1994AICARSullivan JE, Brocklehurst KJ, Marley AE, Carey F, Carling D, Beri RK. Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett. 1994;353(1):33-36. PMID: 7926017. (Early metabolic-effect c… PMID 7926017preclinical, in vivo
2009AICARWorld Anti-Doping Agency. The 2009 Prohibited List: International Standard. WADA. 2009. (First inclusion of AICAR on the banned list under S4.)regulatory / registry
2014AICARMulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev. 2014;35(6):992-1019. PMID: 25216328. (Broader metabolic-modulator context for comparing AMPK-activating approaches with other diabetes-pharmacology stra… PMID 25216328research article
2011AICARHardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011;25(18):1895-1908. PMID: 21937710. (Authoritative AMPK review by a leading AMPK biochemist.) PMID 21937710research article
1999AICARKemp BE, Mitchelhill KI, Stapleton D, Michell BJ, Chen ZP, Witters LA. Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem Sci. 1999;24(1):22-25. PMID: 10087918. (AMPK signaling framework reference.) PMID 10087918research article
1995AICARCorton JM, Gillespie JG, Hawley SA, Hardie DG. 5-Aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem. 1995;229(2):558-565. PMID: 7744080. (Methodology establishing AICAR as the canonical AMPK-a… PMID 7744080research article
1984AICARSabina RL, Swain JL, Olanow CW, Bradley WG, Fishbein WN, DiMauro S, Holmes EW. Myoadenylate deaminase deficiency. Functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle. J Clin Invest. 1984;73(3):720-730. PMID: 6707200. (Context for AMPD… PMID 6707200research article

Related pair pages

More research context

Frequently asked

Have 5-Amino-1MQ and AICAR been studied together?

Researchers have published mechanistic-level co-administration discussion of 5-Amino-1MQ and AICAR. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.

What mechanisms do 5-Amino-1MQ and AICAR share?

5-Amino-1MQ and AICAR do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.

What is the FDA status of 5-Amino-1MQ and AICAR?

5-Amino-1MQ: Not approved. AICAR: Not approved. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.

Where can I find the full research on 5-Amino-1MQ and AICAR?

Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the 5-Amino-1MQ profile and the AICAR profile. The Kalios Stack Research Tool hub lists every compound covered.

Last updated: April 2026